Short-Term Effect of Nutraceutical Fruit Juices on Lipid Metabolism in Patients with Acquired Hypercholesterolemia
暂无分享,去创建一个
[1] G. Cravotto,et al. Nutraceutical Approaches to Dyslipidaemia: The Main Formulative Issues Preventing Efficacy , 2022, Nutrients.
[2] R. Mirnejad,et al. The effect of bergamot (KoksalGarry) supplementation on lipid profiles: A systematic review and meta‐analysis of randomized controlled trials , 2022, Phytotherapy research : PTR.
[3] Ferran Sancho,et al. Food Losses and Waste: A Needed Assessment for Future Policies , 2021, International journal of environmental research and public health.
[4] S. Ramos,et al. Impact of Dietary Flavanols on Microbiota, Immunity and Inflammation in Metabolic Diseases , 2021, Nutrients.
[5] G. Montalescot,et al. 2019 ESC/EAS Guidelines for management of dyslipidaemia: strengths and limitations. , 2020, European heart journal. Cardiovascular pharmacotherapy.
[6] A. D'Angelo,et al. Lipid-lowering nutraceuticals update on scientific evidence , 2020, Journal of cardiovascular medicine.
[7] V. Sorrenti,et al. Evaluation of lipid and cholesterol-lowering effect of bioflavonoids from bergamot extract , 2020, Natural product research.
[8] B. Capaldo,et al. Impact of Grape Products on Lipid Profile: A Meta-Analysis of Randomized Controlled Studies , 2020, Journal of clinical medicine.
[9] M. Pintado,et al. Agro-Food Byproducts as a New Source of Natural Food Additives , 2019, Molecules.
[10] S. Virani,et al. The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk. , 2018, Endocrine reviews.
[11] A. Cicero,et al. An update on the safety of nutraceuticals and effects on lipid parameters , 2018, Expert opinion on drug safety.
[12] R. Krauss,et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease , 2018 .
[13] D. Panagiotakos,et al. Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel , 2017, Nutrition reviews.
[14] F. Fogacci,et al. Food and plant bioactives for reducing cardiometabolic disease risk: an evidence based approach. , 2017, Food & function.
[15] Lale Tokgözoğlu,et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel , 2017, European heart journal.
[16] E. Novellino,et al. A Healthy Balance of Plasma Cholesterol by a Novel Annurca Apple-Based Nutraceutical Formulation: Results of a Randomized Trial , 2017, Journal of medicinal food.
[17] T. Ivanova,et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice , 2016 .
[18] A. Sahebkar,et al. Lipid-modifying effects of nutraceuticals: An evidence-based approach. , 2016, Nutrition.
[19] A. Hoes,et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention , 2016, Atherosclerosis.
[20] J. Hippisley-Cox,et al. Discontinuation and restarting in patients on statin treatment: prospective open cohort study using a primary care database , 2016, British Medical Journal.
[21] M. Banach,et al. Expert opinion: the therapeutic challenges faced by statin intolerance , 2016, Expert opinion on pharmacotherapy.
[22] M. Banach,et al. Is statin-modified reduction in lipids the most important preventive therapy for cardiovascular disease? A pro/con debate , 2016, BMC Medicine.
[23] E. Puigdomènech,et al. Effects of kiwi consumption on plasma lipids, fibrinogen and insulin resistance in the context of a normal diet , 2015, Nutrition Journal.
[24] M. Banach,et al. Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel , 2015, Expert opinion on drug safety.
[25] Lawrence A Leiter,et al. Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management , 2015, European heart journal.
[26] D. Waters,et al. Statin and the risk of renal-related serious adverse events: Analysis from the IDEAL, TNT, CARDS, ASPEN, SPARCL, and other placebo-controlled trials. , 2014, The American journal of cardiology.
[27] G. Duchateau,et al. Consumption of plant sterol-enriched foods and effects on plasma plant sterol concentrations--a meta-analysis of randomized controlled studies. , 2013, Atherosclerosis.
[28] A. Guadarrama,et al. LDL cholesterol-lowering effects of grape extract used as a dietary supplement on healthy volunteers , 2013, International journal of food sciences and nutrition.
[29] A. Minihane,et al. Kiwifruit consumption favourably affects plasma lipids in a randomised controlled trial in hypercholesterolaemic men , 2012, British Journal of Nutrition.
[30] M. Pike,et al. Effect of 2-Month Controlled Green Tea Intervention on Lipoprotein Cholesterol, Glucose, and Hormone Levels in Healthy Postmenopausal Women , 2012, Cancer Prevention Research.
[31] M. Taskinen,et al. [ESC/EAS Guidelines for the management of dyslipidaemias]. , 2011, Revista espanola de cardiologia.
[32] R. Collins,et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010, The Lancet.
[33] G. Boysen,et al. European Guidelines on Cardiovascular Disease Prevention , 2009, International journal of stroke : official journal of the International Stroke Society.
[34] S. Feasson,et al. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20536 high-risk individuals : a randomised placebo-controlled trial. , 2008 .
[35] P. Macfarlane,et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial , 2002, The Lancet.